1 / 25

Monitoring and Evaluation of MDR TB

Monitoring and Evaluation of MDR TB. K ęstutis Miškinis, Medical officer, WHO Ukrainian country office. What is multidrug-resistant tuberculosis (MDR-TB)?. TB bacilli resistant to at least two of the most powerful anti-TB agents: isoniazid and rifampicin ;

Download Presentation

Monitoring and Evaluation of MDR TB

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Monitoring and Evaluation of MDR TB Kęstutis Miškinis, Medical officer, WHO Ukrainian country office

  2. What is multidrug-resistant tuberculosis (MDR-TB)? • TB bacilli resistant to at least two of the most powerful anti-TB agents: isoniazid and rifampicin; • One of the main aims of any national TB program is to minimize the development of drug (multidrug) resistance;

  3. Effectiveness of National TB Programme • High cure rate of new TB cases; • Low (and constantly decreasing) MDR-TB rate; • Ultimately, high case-detection rate; Potential criteria: • Ability to analyze cohort data; • Default and transfer rates less than 10%; • Continual supply of 1st line anti-TB drugs; • Application of DOT in 90% of all cases;

  4. Effectiveness of National TB Programme (con’t.) • Surveillance of anti-TB drug resistance is an essential tool for monitoring the effectivness of TB control programme in any country; • The use of drug-sensitivity tests (DST) was recommended many years ago;

  5. Cause of anti-TB drug resistance • (M)DR-TB is man-made! Naturally drug-resistant organisms arising through spontaneous mutations are selected by inadequate drug regimens; • Reasons – exposure to a single drug due to: • Poor adherence; • Inappropriate prescription; • Irregular drug supply; • Poor drug quality;

  6. MDR-TB • Problems: • longer to treat (up to 24 months); • more expensive (up to 100x); • more side-effects; • demanding follow-up mechanism; • requires complex diagnostics;

  7. Prevalence of (M)DR-TB in some regions WHO / IUATLD / DZK / AKM 1997-1999 Germany Italy Israel Latvia Tomsk Oblast Ivanovo Oblast China Henan Estonia 0% 20% 40% 60% 80% 100% susceptible MDR TB resistant

  8. Countries/settings with MDR rates higher than 10% among combined cases

  9. Boxplots of MDR prevalence rates among New Cases by European Sub-regions 3rd Global Report of WHO

  10. MDR Trends among New Cases in Lithuania and Estonia Confidence-bounded MDR trend among new patients in Lithuania Confidence-bounded MDR trend among new patients in Estonia

  11. Establishment of drug-resistance surveillance system • The sample of specimens should be representative of the TB patients; • The patient’s history should be carefully obtained (available to determine whether the patient has previously received anti-TB drugs); • The laboratory methods should meet internationally recommended standards;

  12. DST methods • Proportion; • Resistance ratio; • Absolute concentration; • BACTEC 460 radiometric; Comparability of data is assured by: • Quality assurance; • Proficiency testing performed by Supranational Reference Laboratories

  13. Choice of drugs Four out of six 1st line drugs: • Isoniazid (H); • Rifampicin (R); • Streptomycin (S); • Ethambutol (E); Why these four? • Widely used; • Resistance can be reliably measured by standardized techniques;

  14. Definitions of resistance • Resistance among previously treated cases (having been treated for tuberculosis for one month or more); • Resistance among new TB cases (denies having had prior anti-TB treatment); • Multi-drug resistance;

  15. National Reference Laboratory Is a reference institution on MDR surveillance. It: • Prepares cultures; • Undertakes identification of Mycobacteria; • Undertakes DST; • Ensures quality of DST performed by regional labs; • Establishes a regular “on-site” supervision;

  16. Organizing of surveillance • Laboratories and diagnostic centers; • Sample size and sampling strategies; • Organization and survey outline (preparation, sampling, training, logistics); • Intake of patients (inclusion criteria, sputum-collection, registration, transport); • National Reference laboratory; • Data management and analysis;

  17. Ukraine • NRL is established, but not functioning; • QA is not implemented; • Proficiency testing hasn’t started yet; • Laboratory standards are defined, but not strictly followed; • Equipment is poor, purchase of new equipment and necessary supplies is often delayed; • Staff needs retraining and rejuvenation;

  18. Trends in Anti-TB-Drug-Resistance in UkraineFeshchenko et al., Ukraine Chemotherapeutical Journal, 2000/3

  19. Trends in Anti-TB-Drug-Resistance in UkraineFeshchenko et al., Ukraine Chemotherapeutical Journal, 2000/3 70 Monodrug resistance Multidrug resistance MDR 60 Polydrug resistance 50 40 Drug resistance (%) 30 20 10 1990 1991 1992 1994 1995 1996 1993 1997 1998 1999 Year

  20. MDR survey results in Donetska oblast (28 02 2006)

  21. Drug Resistance Surveillance • Magnitude and trend of drug resistance prevalence among new and re-treatment cases; • Useful parameter to evaluate current and past treatment programme; • Useful information for selection of effective initial treatment and retreatment regimens;

  22. Should we treat persons with MDR-TB? • Yes…for humanitarian reasons • But health policy is not only driven by values, facts also matter • No... unless it is proven that it is feasible and cost-effective • But can we afford not to respond?

  23. DOTS-Plus: working definition • DOTS-Plus is a case-management strategy under development designed to manage MDR-TB using 2nd line drugs within the DOTS strategy in low- and middle-income countries; DISCLAIMER: DOTS-Plus means DOTS first

  24. Prevention of MDR TB Correct operations of the TB programme: • Diagnosis based on bacteriological examination; • Standard treatment under strict observation (DOT); • Uninterrupted supply of good-quality TB drugs (recommended FDC); • Proper recording and reporting;

More Related